Publisher
Springer Science and Business Media LLC
Reference28 articles.
1. Ioannidis G, Papaioannou A, Hopman WM, Akhtar-Danesh N, Anastassiades T, Pickard L, et al. Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study. CMAJ. 2009;181(5):265–71.
2. Watt JJ, Abimanyl-Ochom J, Sanders KM. Osteoporosis costing all Australians. A new burden of disease analysis-2012–2022, Osteoporosis Australia 2012, ISBN 978-0-9923698-1-1.
3. Karnon J, Edney L, Sorich M. Costs of paying higher prices for equivalent effects on the pharmaceutical benefits scheme. Aust Health Rev. http://dx.doi.org/10.1071/AH15122 .
4. Lin T, Wang C, Cai XZ, Zhao X, Shi MM, Ying ZM, et al. Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis. Int J Clin Pract. 2012;66(4):399–408.
5. Chau D, Becker DL, Coombes ME, Ioannidis G, Adachi JD, Goeree R. Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Canada. J Med Econ. 2012;15(Suppl 1):3–14.
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献